摘要
目的：探讨驳骨灵口服液治疗绝经后骨质疏松症的作用杌理。方法：选择绝经后骨质疏松症患者30例，观察测定其治疗前及治疗6个月后血清中瘦素（Leptin）、一氧化氮（NO）、白介素-6（IL-6）、骨钙素（BGP）、雌二醇（E）含量以及L2-4椎体正位骨密度（BMD）。结果：患者经驳骨灵口服液治疗6个月后，血清中NO、E2、Leptin水平均明显上升（P〈0．01），IL-6、BGP水平均明显下降（P〈0．01）。骨密度（BMD）治疗前后比较，差异无统计学意义（P〉0．05）。结论：驳骨灵口服液为治疗绝经后骨质疏松症的一个有临床应用价值和开发价值的药物。
Objective:To approach the mechanism of action on BOGULINGKOUFUYE (BGLKFY, a TCM composition) used to cure postmenopausalosteoporosis. Methods: 30 cases of patients with postmenopausal osteoporosis were chosen for the experiment, such items as contents of leptin, nitrogen monoxidum (NO), interleukin-6 (IL-6), bone gla protein (BGP) and estradiol (E2) in blood serum and normotopia bone mineral density (BMD) of L2-4 centres were observed and determined pre-and six months post-treatment. Result: After six months of treatment, levels of NO, E2 and Leptin all rose obviously(P< 0.01), those of IL-6 and BGP decreased (P<0.01). On BMD, the difference had not statistically significant pre-and post-treatment (P>0.05) . Conclusion: BGLKFY was value of development and clinical application for curing postmenopausal osteoporosis.
出处
《中医正骨》
2008年第7期6-7,共2页
The Journal of Traditional Chinese Orthopedics and Traumatology
基金
2005年中山市医学院科研基金立项课题项目号:2005046
